Pólipos gástricos: análisis retrospectivo de 41.253 endoscopias digestivas altas

Viudez, L Argüello; Córdova, Henry; Uchima, Hugo; Sánchez-Montes, Cristina; Ginès, Pere; Araujo, Isis K.; González-Suárez, Begoña; Sendino, Oriol; Llach, Josep; Fernández‐Esparrach, Glòria

doi:10.1016/j.gastrohep.2017.01.003

Cited by 15 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study of 269 patients with polypoid lesions, the average age of the patients was 65 and the rate of women was 61% 9 . In another study conducted by Atalay et al 7 , the average age of patients with polyps was 58.4 years and the rate of women was 67.2%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of gastric polyps detected by endoscopy: a single-center study conducted in Turkey’s Southeast Anatolia Region

Ekin

Ebik

Bacaksız

et al. 2020

Preprint

View full text Add to dashboard Cite

Background/Aims: Gastric polyps are often detected incidentally during endoscopic procedures performed for different reasons and may sometimes be manifested by gastric bleeding, pyloric stenosis, iron deficiency anemia and abdominal pain. In our study, we aimed to investigate the demographic data of the cases who were found to have gastric polyps at the gastroenterology endoscopy unit, histologic type of the polyps, their localization and size, and their relationship with Helicobacter Pylori. Materials and Methods: Between September 2016 -September 2019, gastric polyps were detected in 255 of 9771 cases who underwent upper gastrointestinal system endoscopy at the Gastroenterology Endoscopy Unit of . . . . . . .. Training and Research Hospital. Demographic data, endoscopy reports and pathology results of these patients were retrospectively reviewed from the hospital registry system. Results: Of 255 cases included in the study, 160 (62.7%) were female and 95 (37.3%) were male, with a mean age of 56.9 (min: 19, max: 95). A total of 336 polyps were detected in 255 cases, with 1.3 polyps per case. 36 (10.7%) of gastric polyps were found to be fundic gland polyps, 32 (9.5%) were found to be foveolar hyperplasia, 137 (40.8%) were found to be hyperplastic polyps, 5 (1.5%) were found to be xanthomas, and 6 (1.8%) were found to be neuroendocrine tumors. Conclusion: According to this study, 90% of gastric polyps detected endoscopically in southeast Turkey are smaller than 5 mm and located most commonly in the corpus; the most common histologic subtype is hyperplastic polyps.Evaluation of gastric polyps detected by endoscopy: a single-center study conducted in Turkey's Southeast Anatolia Region Background/Aims: Gastric polyps are often detected incidentally during endoscopic procedures performed for different reasons and may sometimes be manifested by gastric bleeding, pyloric stenosis, iron deficiency anemia and abdominal pain. In our study, we aimed to investigate the demographic data of the cases who were found to have gastric polyps at the gastroenterology endoscopy unit, histologic type of the polyps, their localization and size, and their relationship with Helicobacter Pylori.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Histopathological examination reveals gastritis or normal mucosa rather than polyp in approximately 16-37.5% of the lesions considered polyp endoscopically 9 . In our study, histopathological examination revealed gastritis or normal mucosa in 40% of the lesions that were endoscopically considered polyp.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of gastric polyps detected by endoscopy: a single-center study conducted in Turkey’s Southeast Anatolia Region

Ekin

Ebik

Bacaksız

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Gastric polyp is the bulging of the gastric mucosa, usually occurring in the gastric antrum [ 1 ]. The patient may have upper abdominal pain, abdominal distension, dysphagia, or loss of appetite or may have no discomfort; nowadays, the major diagnostic method is gastroscopy [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

“…The patient may have upper abdominal pain, abdominal distension, dysphagia, or loss of appetite or may have no discomfort; nowadays, the major diagnostic method is gastroscopy [ 2 ]. Because the most common histologic type of gastric polyp is the hyperplastic polyp, which has certain risks of turning into a malignant tumor [ 3 ], the main therapy for this disease is gastroscopic polypectomy [ 1 , 4 ]. However, endoscopic therapy is usually associated with certain adverse reactions such as nervousness, nausea, vomiting, and choking cough [ 5 , 6 ], and severe discomfort such as coughing or body movements may lead to aggravation of a pre-existing condition or even interruption of treatment, especially in some critical patients with physiological dysfunction (for instance, respiratory disease or cardiovascular disease) [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Effects of small-dose remifentanil combined with index of consciousness monitoring on gastroscopic polypectomy: a prospective, randomized, single-blinded trial

Liu

Yang

et al. 2018

Trials

View full text Add to dashboard Cite

BackgroundWith the development of painless diagnosis and treatment, remifentanil, a synthetic opioid agonist, is increasingly used in gastroscopy for its rapid, short-term, and potent analgesic effect. However, the dosage of remifentanil used in endoscopy is unclear. Index of consciousness (IOC) is a new anesthesia depth-monitoring indicator that can be divided into index of consciousness 1 (IOC1) and index of consciousness 2 (IOC2); IOC1 is used for estimating a patient’s sedation state, whereas IOC2 reflects analgesic depth. We hypothesized that combining with IOC1 and IOC2 monitoring may be helpful to identify an optimal remifentanil dosage in gastroscopic polypectomy.MethodsOne hundred twenty patients scheduled for gastroscopic polypectomy were enrolled and were randomly assigned to remifentanil 2 ng/mL (group R2), 4 ng/mL (group R4), or 6 ng/mL (group R6), and 40 cases were in each group. During the anesthesia period, remifentanil was kept at the initial given concentration but propofol was adjusted according to IOC1. The primary outcomes were the dosage of propofol and remifentanil. The secondary outcomes were the variety of IOC1 and IOC2, patients’ awakening time, and peri-operative adverse reactions such as hypotension, hypertension, bradycardia, tachycardia, body movements, hypoxemia, therapy interruption, nausea, vomiting, aspiration, and intra-operative awareness.ResultsWith the increasing dosage of remifentanil, the propofol dosage and patients’ awakening time decreased significantly, the morbidity of hypertension and body movements also declined, but the incidence of hypotension, bradycardia, and hypoxemia rose. In group R2, the value of IOC2 remained above 50 during the treatment. However, IOC2 dropped to below 30 at the beginning of the gastroscopy in group R6, and there was statistical difference in hypoxemia between groups R2 and R6 (P <0.05).ConclusionsWith the help of IOC monitoring, we found that a target concentration of remifentanil 4 ng/mL is comparatively ideal in patients under gastroscopic polypectomy.Trial registrationChinese Clinical Trial Register: ChiCTR-OOD-16009489, on October 19, 2016.

show abstract

Gastric Tumors (Other than Adenocarcinoma)

Pitchumoni¹,

Chaubal²,

Desai³

2021

Geriatric Gastroenterology

View full text Add to dashboard Cite

Pólipos gástricos: análisis retrospectivo de 41.253 endoscopias digestivas altas

Cited by 15 publications

References 25 publications

Evaluation of gastric polyps detected by endoscopy: a single-center study conducted in Turkey’s Southeast Anatolia Region

Evaluation of gastric polyps detected by endoscopy: a single-center study conducted in Turkey’s Southeast Anatolia Region

Effects of small-dose remifentanil combined with index of consciousness monitoring on gastroscopic polypectomy: a prospective, randomized, single-blinded trial

Gastric Tumors (Other than Adenocarcinoma)

Contact Info

Product

Resources

About